Our medical and scientific team continues research to improve therapies and offer additional treatment options. Contact a BioXcellerator Patient Advocate to see if new treatments are available for your condition.

Schedule Your Free Consultation

Free Consultation

Top Stem Cell Company BioXcellerator wins prestigious Arnold Caplan Loyalty Award

Arnold Caplan Award

Arnold Caplan Award

On (October), 06, 2019 BioXcellerator received significant recognition for its leadership in stem cell research at the 2nd International Symposium of Stem Cells in Cancun, Mexico. The company received the prestigious Arnold Caplan Medal Loyalty Award for its leadership in advanced stem cell therapies.

The award was named in honor of Dr. Arnold Caplan, a Professor of Biology and the Director of the Skeletal Research Center at Case Western Reserve University — and known by leading scientists as the “father of mesenchymal stem cells.”

“Dr. Caplan first discovered mesenchyme stem cells in the 1980s,” explains Dr. Karolyn Halpert, BioXcellerator Medical CEO. “These are cells that can easily be differentiated — or changed — into other types of cells change depending on what type of therapy a patient needs.”

“By the 1990s, Dr. Caplan and his team had developed the technology needed to isolate these stem cells so they could grow in a laboratory setting and be used to treat patients. These are multipotent cells, so they become an excellent option to treat a wide variety of joint and tissue injuries in cartilage, tendons, and ligaments – and to treat diseases such as osteoarthritis,” she adds.

Improving Treatment Protocols and Effectiveness

According to Dr. Halpert, Dr. Caplan’s research has helped other scientists improve treatments through advancements in how these mesenchymal stem cells are introduced into patients.

“In some cases, we inject cells directly into muscles, joints, or veins,” she explains, “But more recent research reveals that a newer method — using steam to deliver cells into the upper sinus can help treat patients with MS, ALS, or Parkinson’s disease.”

Skip to content